UNSPSC 51272108: Paridocaine

This classification denotes an anesthetic agent with the molecular formula C17H26N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 795182TM5G, chemically known as benzoic acid, p-(butylamino)-, 1-methyl-4-piperidyl ester but generally known as paridocaine, which bears US NIH Compound Identifier 23551. European Medicines Agency schedules Paridocaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09628MIG.

UNSPSC 51272108 Paridocaine is a Commodity-tier code that in recent state and local procurement activity encompasses a broader range of pharmaceutical and drug-management products than its nominal scope suggests. Recent solicitations show state and local buyers acquiring naloxone and drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing, and exploring direct-to-manufacturer pharmacy benefit program models. The issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP), reflecting a mix of direct county procurement and broader cooperative vehicles serving multiple jurisdictions.

Activity spans Florida, Texas, Minnesota, and Oregon through recent solicitations. Seminole County, Florida released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; bids closed July 26, 2023 (note: the listed due date appears to contain a year discrepancy in the source). The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, as an exploratory market intelligence effort to gather vendor capabilities for implementing a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program that would bypass traditional pharmacy benefit managers and wholesalers. MMCAP, administered by the Minnesota Department of Administration, posted RFP S1070000015802 on January 20, 2026, with proposals due March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson) with contract terms effective July 1, 2026.